PD-004Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Marmorino, F.; Cremolini, C.; Loupakis, F.; Antoniotti, C.; Barbara, C.; Dargenio, F.; Miraglio, E.; Masi, G.; Salvatore, L.; Schirripa, M.; Borelli, B.; Marcucci, L.; Antonuzzo, L.; Chiara, S.; Banzi, C.; Amoroso, D.; Bonetti, A.; Martignetti, A.; Paris, M.; Boni, L.; Tomcikova, D.; Falcone, A.

期刊名称Annals of Oncology
作者Marmorino, F.; Cremolini, C.; Loupakis, F.; Antoniotti, C.; Barbara, C.; Dargenio, F.; Miraglio, E.; Masi, G.; Salvatore, L.; Schirripa, M.; Borelli, B.; Marcucci, L.; Antonuzzo, L.; Chiara, S.; Banzi, C.; Amoroso, D.; Bonetti, A.; Martignetti, A.; Paris, M.; Boni, L.; Tomcikova, D.; Falcone, A.
卷第27卷
印刷ISSN0923-7534
电子ISSN1569-8041
文件大小64.39KB
发表时间2016-06
DOI10.1093/annonc/mdw200.04

发现好书期刊，享受阅读乐趣

PD-004Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study